Los puntos clave no están disponibles para este artículo en este momento.
In this study, first-line treatment with nivolumab-ipilimumab combination therapy was not found to be cost-effective at current prices despite clinical trial data indicating that this regimen increases overall survival among patients with advanced NSCLC.
Courtney et al. (Mon,) studied this question.